GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Biogen Idec Inc (BIIB) [hlAlert]

Rating:
Buy BIIB
up 6.99 %

Biogen Idec Inc (BIIB) upgraded to Buy with price target $360 by Standpoint Research

Posted on: Thursday,  Jan 7, 2016  3:25 PM ET by Standpoint Research

Standpoint Research rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 01/07/2016, when the stock price was $284.59. Since
then, Biogen Idec Inc has gained 6.99% as of 01/07/2016's recent price of $304.49.
If you would have followed this Standpoint Research's recommendation on BIIB, you would have gained 6.99% of your investment in 0 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Standpoint Research provides independent equity research that is free from the conflicts of asset management, investment banking, proprietary trading, and fee-for-research arrangements. We provide thorough analysis, diagnostics and forecasts on domestic and international equities and markets backed by alpha-generating variables back-tested on many years of data. Standpoint Research currently advises and sells its research to pension funds, hedge funds and asset management firms. Wall Street analysts have an optimistic bias, while we are more objective. In fact some of the variables in our model that are looked at as positives by Wall Street actually carry negative weight in our model. We have a strict discipline that includes running our proprietary 155-variable valuation and diagnostics model with a personal and subjective overlay that has been proven to add value. The effectiveness is demonstrated through our impressive track record of recommendations.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/7/2016 3:25 PM Buy
None
284.59 360.00
as of 12/31/2010
1 Week   
1 Month   
3 Months up  12.77 %
1 YTD up  15.30 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/28/2010 11:25 AM Hold
None
63.29
1/19/2010 8:25 AM Buy
None
54.89 70.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy